ELC52: a novel megakaryocytic leukemia cell line with a CALR type 1 mutation

Yukiya Yamamoto,Sachiko Iba,Yoko Inaguma,Akinao Okamoto,Akihiro Abe

DOI: https://doi.org/10.1038/s41375-024-02434-0

2024-10-09

Leukemia

Abstract:Myeloproliferative neoplasms (MPNs) are clonal hematopoietic cell diseases characterized by gain-of-function mutations in the JAK2, CALR, and MPL genes [1, 2]. CALR is a chaperone protein that resides primarily in the endoplasmic reticulum and is involved in various cellular processes, including cell adhesion. CALR mutations in exon 9 are the second most frequently detected mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) [1, 2]. Mutant CALR enables pathogenic binding with MPL, leading to ligand-independent activation of the MPL signaling pathway [3,4,5]. Therefore, the mutant CALR/MPL complex is regarded as an important target for controlling CALR-mutated MPNs [1]. JAK2 mutations are the most frequently detected in MPNs [1, 2]. Cell line models harboring JAK2 mutations, such as HEL 92.1.7 (HEL), not only mimic MPNs in in vitro experiments, but also serve as a useful resource in developing therapeutics targeting mutant JAK2 [6]. MARIMO is a unique cell line that expresses a mutant CALR [7, 8]. However, MARIMO cells do not express MPL, which is accompanied by inactivation of its downstream signaling pathway, including JAK/STAT/ERK. Therefore, MARIMO cells may not be suitable for studying oncogenic functions of mutant CALR [7, 8]. To the best of our knowledge, no other cell lines have been described as ideal models for oncogenic functions of mutant CALR. Here, we report a patient-derived megakaryocytic leukemia cell line, designated ELC52, which is driven by a mutant CALR, and is a potentially useful model for investigating megakaryocyte biology. We established a leukemia cell line designated ELC52 (ET-overt Leukemia cells with a CALR 52-bp deletion). ELC52 cells were obtained from bone marrow of a 67-year-old male patient. The patient was initially diagnosed with an ET. After a stable phase of 26 years of treatment with hydroxycarbamide or busulfan, myeloid leukemia transformation occurred. The patient was admitted because of fever, fatigue, and priapism. A full blood count showed a hemoglobin level of 8.0 g/dL, platelet count of 14.2 × 10 9 /L, and white blood cell count of 18.6 × 10 9 /L, of which myeloperoxidase-positive blasts accounted for 37%. Bone marrow samples for in vitro culture, in which immature blasts accounted for 68.8% after five months of leukemia transformation, were collected under protocols approved by the institutional review board of Fujita Health University and with written, informed consent in accordance with the Declaration of Helsinki.

oncology,hematology